NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
Actuate Therapeutics Inc.
Thomas Jefferson University
University of Utah
Washington University School of Medicine
National Cancer Institute (NCI)